Search research articles
Contact Us
Filters
Showing results (51-60 of 61) with videos related to
Page
of 7
Sort By:
Biorxiv : the Preprint Server for Biology
|
February 14, 2024
Pharmacological Enhancement of Adult Hippocampal Neurogenesis Improves Behavioral Pattern Separation in Young and Aged Mice
Wei-Li Chang, Karly Tegang, Benjamin A Samuels, et al.
Pharmaceutical Research
|
April 12, 2022
Unbound Brain-to-Plasma Partition Coefficient, K<sub>p,uu,brain</sub>-a Game Changing Parameter for CNS Drug Discovery and Development
Irena Loryan, Andreas Reichel, Bo Feng, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 27, 2010
Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors
Emmanuel Pinard, Daniela Alberati, Markus Bender, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 4, 2009
Discovery of the imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepine scaffold as a novel, potent and selective GABA(A) alpha5 inverse agonist series
Guido Achermann, Theresa M Ballard, Francesca Blasco, et al.
The Lancet. Oncology
|
April 11, 2022
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
Ulrike Nitz, Oleg Gluz, Monika Graeser, et al.
International Journal of Cancer
|
February 3, 2021
Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials
Monika Graeser, Simone Schrading, Oleg Gluz, et al.
Journal of Medicinal Chemistry
|
April 18, 2013
β-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease
Hans Hilpert, Wolfgang Guba, Thomas J Woltering, et al.
Frontiers in Immunology
|
November 6, 2024
Evaluation of STK17B as a cancer immunotherapy target utilizing highly potent and selective small molecule inhibitors
Felix Scheuplein, Florian Renner, John E Campbell, et al.
Journal of Medicinal Chemistry
|
May 25, 2010
Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia
Emmanuel Pinard, Alexander Alanine, Daniela Alberati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 11, 2022
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer
Ulrike A Nitz, Oleg Gluz, Sherko Kümmel, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 61) with videos related to
Sort By:
Page
of 7
Biorxiv : the Preprint Server for Biology
|
February 14, 2024
Pharmacological Enhancement of Adult Hippocampal Neurogenesis Improves Behavioral Pattern Separation in Young and Aged Mice
Wei-Li Chang, Karly Tegang, Benjamin A Samuels, et al.
Pharmaceutical Research
|
April 12, 2022
Unbound Brain-to-Plasma Partition Coefficient, K<sub>p,uu,brain</sub>-a Game Changing Parameter for CNS Drug Discovery and Development
Irena Loryan, Andreas Reichel, Bo Feng, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 27, 2010
Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors
Emmanuel Pinard, Daniela Alberati, Markus Bender, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 4, 2009
Discovery of the imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepine scaffold as a novel, potent and selective GABA(A) alpha5 inverse agonist series
Guido Achermann, Theresa M Ballard, Francesca Blasco, et al.
The Lancet. Oncology
|
April 11, 2022
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
Ulrike Nitz, Oleg Gluz, Monika Graeser, et al.
International Journal of Cancer
|
February 3, 2021
Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials
Monika Graeser, Simone Schrading, Oleg Gluz, et al.
Journal of Medicinal Chemistry
|
April 18, 2013
β-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease
Hans Hilpert, Wolfgang Guba, Thomas J Woltering, et al.
Frontiers in Immunology
|
November 6, 2024
Evaluation of STK17B as a cancer immunotherapy target utilizing highly potent and selective small molecule inhibitors
Felix Scheuplein, Florian Renner, John E Campbell, et al.
Journal of Medicinal Chemistry
|
May 25, 2010
Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia
Emmanuel Pinard, Alexander Alanine, Daniela Alberati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 11, 2022
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer
Ulrike A Nitz, Oleg Gluz, Sherko Kümmel, et al.
Page
of 7